Clinical Trial

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mirdametinib, a methyl ethyl ketone (MEK) inhibitor, works by blocking the action of an abnormal protein that signals cancer cells to multiply. This may help slow or stop the spread of cancer cells. Giving mirdametinib may be effective in treating patients with relapsed or refractory CLL or SLL.
Protocol Amendment History 86 amendments
This ClinicalTrials.gov record has been amended 86 times since 2025-07-11; most recent amendment 2026-06-17.
Status change: Not Yet Recruiting → Recruiting 2025-12-24
Trial Details
NCT Number NCT07061951
Lead Sponsor National Cancer Institute (NCI)
Conditions Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Enrollment 20 participants
Start Date 2026-05-27
Primary Completion 2030-02-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-31